NEW YORK, September 25, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and United Therapeutics Corporation (NASDAQ: UTHR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6765-100free.
--
Tekmira Pharmaceuticals Corp. Research Reports
On September 22, 2014, Tekmira Pharmaceuticals Corp. (Tekmira) announced that the U.S. Food and Drug Administration (FDA) has authorized the use of its Ebola treatment under expanded access protocols to patients with confirmed or suspected Ebola virus infections. Commenting on the approval, Tekmira's President and CEO Dr. Mark J. Murray said, "In the US, the FDA has granted expanded access use of TKM-Ebola under our Investigational New Drug application (IND) and Health Canada has established a similar framework, both of which allow the use of our investigational therapeutic in more patients." Dr. Murray also informed that "TKM-Ebola has been administered to a number of patients and the repeat infusions have been well tolerated." Cheering the development, the Company's stock gained 17.11% to end the trading session at $23.61. The full research reports on Tekmira are available to download free of charge at:
http://www.analystsreview.com/Sep-25-2014/TKMR/report.pdf
--
Regeneron Pharmaceuticals, Inc. Research Reports
On September 22, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron) announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has received approval for the EYLEA (aflibercept) Injection for the treatment of myopic choroidal neovascularization (myopic CNV) in Japan. EYLEA, which is jointly developed by Regeneron and Bayer HealthCare, has already been approved in Japan for the treatment of patients with neovascular age-related macular degeneration (wet AMD), and macular edema secondary to central retinal vein occlusion (CRVO). Myopic CNV is a disease of the retina where new, abnormal blood vessels grow into the retina in persons who are severely myopic, which is common in Asia. The Company said that its EYLEA is designed to block the growth of new blood vessels and decrease the ability of fluid to pass through blood vessels in the eye. The full research reports on Regeneron are available to download free of charge at:
http://www.analystsreview.com/Sep-25-2014/REGN/report.pdf
--
Valeant Pharmaceuticals International, Inc. Research Reports
On September 15, 2014, Valeant Pharmaceuticals International, Inc. (Valeant) announced that its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem all of the outstanding $500.0 million aggregate principal amount of its 6.75% Senior Notes due 2017 on October 15, 2014. Valeant informed that a copy of the irrevocable notice of redemption with respect to the remaining Notes has already been mailed to record holders of the Notes by The Bank of New York Mellon Trust Company, N.A. as trustee under the indenture governing the Notes. The full research reports on Valeant are available to download free of charge at:
http://www.analystsreview.com/Sep-25-2014/VRX/report.pdf
--
Teva Pharmaceutical Industries Ltd. Research Reports
On September 15, 2014, CNW reported that Teva Canada Limited (Teva Canada), a subsidiary of Teva Pharmaceutical Industries Ltd., has announced that its application for the generic version of Ezetrol has been approved by the Canadian Health Department for treatment of patients with primary (heterozygous familial and non-familial) hypercholesterolemia. Teva's generic Ezetimibe is indicated as an adjunct to lifestyle changes, including diet, when the response to diet and other non-pharmacological measures alone has been inadequate. As per IMS Brogan sales data as of July 10, 2014, Ezetrol had annual sales of approximately $189 million in Canada. "Teva Canada is committed to playing our part in ensuring Canadians with high cholesterol have access to affordable and safe medications as soon as possible," said Doug Sommerville, Senior Vice-President and General Manager, Teva Canada Limited. The full research reports on Teva are available to download free of charge at:
http://www.analystsreview.com/Sep-25-2014/TEVA/report.pdf
--
United Therapeutics Corporation Research Reports
On September 22, 2014, the stock of United Therapeutics Corporation (United Therapeutics) resumed its northward journey, after pausing in the previous session, and hit a fresh 52-week high before ending the day with a gain of 2.74% at $133.68. Shares in United Therapeutics opened at $130.14, and fluctuated in the range of $128.34 - $134.19, with a total of 1.47 million shares changing hands. The stock also remained well above its 50-day and 200-day moving averages of $101.25 and $99.21, respectively. The stock has gained 13.45% since August 29, 2014, when the Company announced that a court has ruled in favor of the Company in its case against Sandoz, Inc. regarding United Therapeutics' Remodulin product. The full research reports on United Therapeutics are available to download free of charge at:
http://www.analystsreview.com/Sep-25-2014/UTHR/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
